PharmaShots Weekly Snapshot (February 03-07, 2020)

  1. WHO to Accelerate Global Research and Innovation Against Corona Virus

Published: Feb 06, 2020 | Tags: WHO, Accelerate, Global, Research, Innovation, Against, Corona Virus

2.  Curis Amends its Existing Collaboration with Aurigene for the Development and Commercialization of CA-170

Published: Feb 07, 2020 | Tags: Curis, Amends, Existing Collaboration, Aurigene, Development, Commercialization, CA-170

3.  Novo Nordisk to Invest ~$117.4M in Expansion of its Production Facilities in Denmark

Published: Feb 07, 2020 | Tags: Novo Nordisk, Invest, ~$117.4M, Expansion, Production Facilities, Denmark

4.  Collegium to Acquire US Rights of Assertio’s Nucynta Franchise for $375M

Published: Feb 06, 2020 | Tags: Collegium, Acquire, US, Rights, Assertio, Nucynta Franchise, $375M

5.  Merck & Co. to Initiate P-II Study of MK-5890 for Non-Small Cell Lung Cancer

Published: Feb 06, 2020 | Tags: Merck & Co., Initiates, P-II, Study, MK-5890, Non-Small Cell Lung Cancer

6. Roche Reports Results of Tecentriq (atezolizumab) + Avastin (bevacizumab) in P-III IMbrave150 Study in Chinese Patients with Hepatocellular Carcinoma

Published: Feb 07, 2020 | Tags: Roche, Reports, Results, Tecentriq, atezolizumab, Avastin, bevacizumab, P-III, IMbrave150 Study, Chinese Patients, Hepatocellular Carcinoma

7. Almirall Collaborates with Plug and Play to Offer Digital Solutions in Dermatology

Published: Feb 06, 2020 | Tags: Almirall, Collaborates, Plug and Play, Offer, Digital Solutions, Dermatology

8. Bridge Biotherapeutics Signs a License Agreement with Konkuk University for its Back-Eye Disease Therapy

Published: Feb 06, 2020 | Tags: Bridge Biotherapeutics, Signs, License Agreement, Konkuk University, Back-Eye Disease Therapy

9. Nestle Health Science Signs a Worldwide Exclusive Agreement with VALBIOTIS to Develop and Commercialize TOTUM-63 for Reducing the Risk of T2D

Published:  Feb 05, 2020 | Tags: Nestle Health Science, Signs, Worldwide, Exclusive Agreement, VALBIOTIS, Develop, Commercialize, TOTUM-63, Reducing, T2D

10. Roche Reports Results of Risdiplam in SUNFISH Part 2 Study for Patients with Type 2 Or 3 Spinal Muscular Atrophy

Published: Feb 06, 2020 | Tags: Roche, Reports, Results, Risdiplam, SUNFISH Part 2, Study, Patients, Type 2 Or 3, Spinal Muscular Atrophy

11.  Fresenius Kabi Reports the Availability of Glucagon Emergency Medicine Kit to Treat Hypoglycemia in the US

Published: Feb 05, 2020 | Tags: Fresenius Kabi, Reports, Availability, Glucagon Emergency Medicine Kit, Hypoglycemia, US

12.  Sanofi Reports Results of SAR442168 in P-IIb Study for Relapsing Multiple Sclerosis

Published: Feb 06, 2020 | Tags: Sanofi, Reports, Results, SAR442168, P-IIb, Study, Relapsing Multiple Sclerosis

13. Merck & Co. Collaborates with Atreca to Identify Novel Antibody Targets in Oncology

Published: Feb 05, 2020 | Tags: Merck & Co., Collaborates, Atreca, Identify, Novel Antibody Targets, Oncology

14. Johnson & Johnson Initiates the Development of Vaccines Against Coronavirus

Published: Feb 06, 2020 | Tags: Johnson & Johnson, Initiates, Development, Vaccines, Coronavirus

15. Alector’s AL101 Receives FDA’s Fast Track Designation to Treat Frontotemporal Dementia

Published: Feb 05, 2020 | Tags: Alector, AL101, Receives, FDA, Fast Track Designation, Treat, Frontotemporal Dementia

16. Navrogen and Levena Collaborate to Develop ADCs for Humoral Immuno-Suppressed Cancers

Published: Feb 05, 2020 | Tags:  Navrogen, Levena, Collaborate, ADCs, Humoral Immuno-Suppressed Cancers

17. Seqirus’ Audenz Receives the US FDA’s Approval as the First Adjuvanted Cell-Based Pandemic Influenza A (H5N1) Vaccine

Published: Feb 03, 2020 | Tags: Seqirus, Audenz, Receives, US, FDA, Approval, First, Adjuvanted, Cell-Based, Pandemic, Influenza A, H5N1 Vaccine

18. Merck & Co. to Spin-Off its Non-Core Business into a New Company to Focus on its Core Therapy Areas

Published: Feb 05, 2020 | Tags: Merck, Spin -Off, Non-Core Business, New Company, Core Therapy Areas

19. The US FDA Grants Emergency Use Authorization for Coronavirus Diagnostic Test

Published: Feb 04, 2020 | Tags: US, FDA, Grants, Emergency Use Authorization, Coronavirus Diagnostic Test

20. AbbVie’s Rinvoq (upadacitinib) Receives ANVISA’s Approval for Rheumatoid Arthritis

Published: Feb 04, 2020 | Tags: AbbVie, Rinvoq, upadacitinib, Receives, ANVISA, Approval, Rheumatoid Arthritis

21. BioMotiv and BMS to Launch Anteros Pharmaceuticals

Published: Feb 05, 2020 | Tags: BioMotiv, BMS, Launch, Anteros Pharmaceuticals

22. Regeneron Expands its Existing Collaboration with HHS’BARDA to Develop Antibody Therapies for Coronavirus

Published: Feb 04, 2020 | Tags: Regeneron, Expands, Existing Collaboration, HHS, BARDA, Develop, Antibody Therapies, Coronavirus

23. GSK Reports EMA’s Acceptance of MAA for Belantamab Mafodotin to Treat Relapsed or Refractory Multiple Myeloma

Published: Feb 04, 2020 | Tags: GSK, Reports, EMA, Acceptance, MAA, Belantamab Mafodotin, Treat, Relapsed or Refractory, Multiple Myeloma

24. CELLINK Expands its Multi-Target Collaboration with AstraZeneca for Drug Discovery

Published: Feb 04, 2020 | Tags: CELLINK, Expands, Multi-Target, Collaboration, AstraZeneca, Drug Discovery

25. Boehringer Ingelheim Reports Real-World Data for Spiriva Respimat (tiotropium bromide) Inhalation Spray 1.25mcg in Patients with Asthma

Published: Feb 04, 2020 | Tags: Boehringer Ingelheim, Reports, Real-World Data, Spiriva Respimat, (tiotropium bromide), Inhalation Spray, 1.25mcg, Patients, Asthma

26. Kyowa Kirin Terminates its Agreement with Zeria Pharmaceuticals for ASACOL (mesalazine)

Published: Feb 04, 2020 | Tags: Kyowa Kirin, Terminates, Agreement, Zeria Pharmaceuticals, ASACOL, (mesalazine)

27. Bio-Thera Reports Results of BAT1706 (biosimilar, bevacizumab) in P-III Trial for Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Published: Feb 04, 2020 | Tags: Bio-Thera, Reports, Results, BAT1706, biosimilar, bevacizumab, P-III, Non-Squamous Non-Small Cell Lung Cancer, NSCLC

28. IMIDomics Collaborates with Gossamer Bio to Develop Therapies for Treating Immune-Mediated Inflammatory Diseases

Published: Feb 04, 2020 | Tags: IMIDomics, Collaborates, Gossamer Bio, Develop, Therapies, Treating, Immune-Mediated Inflammatory Diseases

29. Danaher Receives S.Korean FTC’s Conditional Approval for its $21.4B GE Biopharma Acquisition

Published: Feb 04, 2020 | Tags: Danaher, Receives, S.Korean FTC, Conditional Approval, $21.4B, GE Biopharma Acquisition

30. Amgen Launches Amgevita (biosimilar, adalimumab) for the Treatment of Inflammatory Diseases in Brazil

Published: Feb 03, 2020 | Tags: Amgen, Launches, Amgevita, biosimilar, adalimumab, Treatment, Inflammatory Diseases, Brazil

31. Pfizer’s Ruxience (biosimilar, rituximab) Receives CHMP’s Positive Opinion for Cancer and Autoimmune Diseases

Published: Jan 31, 2020 | Tags: Pfizer, Ruxience, biosimilar, rituximab, Receives, CHMP, Positive Opinion, Cancer, Autoimmune Diseases

32. Teva Reports Results of Ajovy (fremanezumab) in Two P-II/III Clinical Studies for the Treatment of Migraine in Japan

Published: Feb 03, 2020 | Tags: Teva, Reports, Results, Ajovy, fremanezumab, Two, P-II/III, Clinical Studies, Treatment, Migraine, Japan

33. GSK Collaborates with CEPI to Develop Vaccine Against Corona Virus

Published: Feb 03, 2020 | Tags: GSK, Collaborates, CEPI, Develop, Vaccine, Against, Corona Virus

34. Eli Lilly Launches Reyvow (lasmiditan) C-V for the Treatment of Migraine in the US

Published: Feb 03, 2020 | Tags: Eli Lilly, Launches, Reyvow, lasmiditan, C-V, Treatment, Migraine, US

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post